Eyepoint Pharmaceuticals Inc (EYPT)

Feb 21, 2025

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN

Feb 21, 2025

Feb 20, 2025

Adversity is less terrifying than hope: EyePoint Pharmaceuticals Inc (EYPT) - SETE News

Feb 20, 2025

Feb 17, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Feb 17, 2025

Feb 17, 2025

EyePoint Pharmaceuticals Grants Stock Options to New Employees as Inducement Awards - Nasdaq

Feb 17, 2025

Feb 16, 2025

(EYPT) Trading Advice - Stock Traders Daily

Feb 16, 2025

Feb 15, 2025

230,745 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by abrdn plc - MarketBeat

Feb 15, 2025

Feb 13, 2025

TD Cowen maintains EyePoint stock Buy rating, $20 target - MSN

Feb 13, 2025

Feb 10, 2025

Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $26.63 - MarketBeat

Feb 10, 2025

Feb 10, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from Chardan Capital - MarketBeat

Feb 10, 2025

Feb 09, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week LowTime to Sell? - MarketBeat

Feb 09, 2025

Feb 08, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns Buy Rating from Chardan Capital - Armenian Reporter

Feb 08, 2025

Feb 07, 2025

EyePoint's decline following positive data makes no sense, says analyst - MSN

Feb 07, 2025

Feb 07, 2025

EyePoint Pharmaceuticals Inc [EYPT] Shares Fall Approximately -76.18% Over the Year - Knox Daily

Feb 07, 2025

Feb 07, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan Capital - Armenian Reporter

Feb 07, 2025

Feb 06, 2025

Investors unsure on EyePoint’s Duravyu blockbuster claim - The Pharma Letter

Feb 06, 2025

Feb 06, 2025

A significant driver of top-line growth: EyePoint Pharmaceuticals Inc (EYPT) - SETE News

Feb 06, 2025

Feb 06, 2025

There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register

Feb 06, 2025

Feb 06, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Analysts - ETF Daily News

Feb 06, 2025

Feb 06, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts - Defense World

Feb 06, 2025

Feb 06, 2025

EyePoint stock jumps 10% on Duravyu study results - MSN

Feb 06, 2025

Feb 05, 2025

(EYPT) Investment Analysis - Stock Traders Daily

Feb 05, 2025

Feb 05, 2025

Analyzing the Impact of Earnings Reports on EyePoint Pharmaceuticals Inc Inc. (EYPT) Price Performance - The InvestChronicle

Feb 05, 2025

Feb 05, 2025

Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Rises By 9.9% - MarketBeat

Feb 05, 2025

Feb 05, 2025

EyePoint Pharmaceuticals : Investor Presentation February 2025 - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

EyePoint stock jumps 10% on Duravyu study results (EYPT:NASDAQ) - Seeking Alpha

Feb 05, 2025

Feb 05, 2025

EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

Collegium Appoints Nancy S. Lurker to its Board of Directors - citybiz

Feb 05, 2025

Feb 05, 2025

EyePoint’s decline following positive data makes no sense, says analyst By Investing.com - Investing.com Nigeria

Feb 05, 2025

Feb 05, 2025

EyePoint's decline following positive data makes no sense, says analyst By Investing.com - Investing.com South Africa

Feb 05, 2025

Feb 05, 2025

Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan

Feb 05, 2025

Feb 05, 2025

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - The Manila Times

Feb 05, 2025

Feb 05, 2025

EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com - Investing.com South Africa

Feb 05, 2025

Feb 05, 2025

Should investors be concerned about EyePoint Pharmaceuticals Inc (EYPT)? - US Post News

Feb 05, 2025

Feb 05, 2025

EyePoint Pharmaceuticals stock sinks following clinical trial results - Investing.com

Feb 05, 2025

Feb 05, 2025

Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds - StockTitan

Feb 05, 2025

Feb 04, 2025

Analyzing EyePoint Pharmaceuticals Inc (EYPT) After Recent Trading Activity - Knox Daily

Feb 04, 2025

Feb 04, 2025

Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex

Feb 04, 2025

Feb 02, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update - Defense World

Feb 02, 2025

Jan 30, 2025

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival (NASDAQ:EYPT) - Seeking Alpha

Jan 30, 2025

Jan 30, 2025

EyePoint Pharmaceuticals' CEO Jay S. Duker to Speak at Guggenheim SMID Cap Biotech Conference on February 6, 2025 - Nasdaq

Jan 30, 2025

Jan 30, 2025

EyePoint to Present at Guggenheim SMID Cap Biotech Conference - The Manila Times

Jan 30, 2025

Jan 30, 2025

Inside EyePoint's Strategy: CEO Set to Reveal Latest Developments in Retinal Disease Treatment - StockTitan

Jan 30, 2025

Jan 27, 2025

Franklin Resources Inc. Expands Portfolio with EyePoint Pharmace - GuruFocus.com

Jan 27, 2025

Jan 25, 2025

Long Term Trading Analysis for (EYPT) - Stock Traders Daily

Jan 25, 2025

Jan 25, 2025

Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance

Jan 25, 2025

Jan 23, 2025

Brokers Offer Predictions for EYPT FY2025 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% HigherShould You Buy? - MarketBeat

Jan 22, 2025

Jan 22, 2025

Research Analysts Issue Forecasts for EYPT FY2025 Earnings - MarketBeat

Jan 22, 2025